Product Images Pregabalin

This is a warning label for Pregabalin capsules manufactured by ScieGen Pharmaceuticals. The label provides information on dosage, ingredients, and potential side effects. It also warns that the medication may be habit-forming and should be kept out of the reach of children. The manufacturing company's address is also provided.*

The text seems to be a chart displaying the percentage of patients who have improved, with some numbers slightly shifted and the addition of a line that says "Percent Improvement in Pain from Baseline". Without additional context, it is difficult to provide a more specific description.*

The text suggests that there is a table or graph showing percent improvement in pain from baseline for patients who took Pregabalin 160 mg for three days. The data includes percentages of improvement ranging from 2 to 100 percent. However, there are some random numbers and symbols that do not seem to fit in, and the text does not provide a clear description of the entire chart or table. Therefore, the information provided is not helpful.*

This text appears to be a chart displaying the percentage of patients improved and the percentage improvement in pain from baseline for different medications, including Pregatalin and Pregabalin. The chart also includes some numerical values that are difficult to interpret, as they are not arranged in a clear format.*

Not available.*

This looks like a table showing the dosage of two medications (Fregabalin and Pregataiin) as well as a placebo, and the percentage of patients who experienced improvement in pain after taking them. There is also a chart showing the percentage of improvement in pain from baseline for each treatment. It appears that Fregabalin was given at a higher dose than Pregataiin, but it is not clear what condition the patients were being treated for.*

The text appears to be a table representing a study with different dosages of a medication (Placebo, 50mg/day, 150mg/day, 300mg/day, 600mg/day) and its effects. The text mentions that the study was statistically significant compared to the placebo group.*

This is a graph depicting the percent of patients who showed improvement in pain based on different doses of Pregabalin (300mg and 450mg) as well as placebo. The x-axis shows the percent improvement in pain from baseline while the y-axis shows the percentage of patients who experienced a specific level of pain improvement.*

This appears to be a chart displaying the estimated percentage of subjects without LTR (likely a medical term) over a period of 120 days. There are two sections labeled "Progabain" and "Placebo." The percentages range from 100% down to 0%, and there are various markers for each 10-day interval. It is not clear what LTR refers to or what study this chart is from.*

The text seems to show a chart or table that displays the percentage of subjects who have improved. There are two groups, one that received pregabalin and one that received a placebo. The percentage of improvement is shown from baseline up to week 16. However, as the text is not clear, there may be some discrepancies or errors in the interpretation of the data.*

This appears to be a formula used to calculate the creatinine clearance (CLCT) of a patient based on their age, weight, and serum creatinine level. The formula involves subtracting the patient's age in years from 140 and multiplying the result by their weight in kilograms. For female patients, the result is then multiplied by 0.85. The final step involves multiplying the result by the patient's serum creatinine level measured in milligrams per deciliter (mg/dL), and dividing by 72. This formula is often used to estimate kidney function in patients with renal impairment.*